On November 4, 2026, Evident Vascular announced that the FDA had granted 510(k) clearance to its Evident Vascular Guidance System and peripheral imaging catheters.
The system is intended for intravascular ultrasound (IVUS) examination during peripheral vascular interventions—not, based on the reports, for coronary procedures.
The company says the platform combines high-fidelity imaging, dynamic frequency control (DFC), flushless plug-and-play catheters, an intuitive interface, and hands-free voice control.
Evident describes an onboard AI workstation and real-time image processing using NVIDIA accelerated computing. The announcement presents AI as a platform capability, with further AI features planned as clinical experience and data accumulate.
The clearance establishes a regulatory foundation for the company’s next steps; the reports do not provide a commercial launch date or clinical outcome data.
Sources:
Evident Vascular Receives FDA Clearance for High-Fidelity AI Powered IVUS Imaging Platform
Evident Vascular secures FDA clearance for IVUS imaging system
FDA Clears Emerging AI-Enabled Platform for Intravascular Ultrasound | Diagnostic Imaging
Evident Vascular Raises Series B Financing to Advance AI- ...
Evident Vascular Receives FDA Clearance for High-Fidelity AI Powered IVUS Imaging Platform
Evident Vascular Raises Series B Financing to Advance AI ...
Evident Vascular Exits Stealth with $35 Million Series A ...
Evident Vascular Receives FDA Clearance for High-Fidelity AI Powered IVUS Imaging Platform
Evident Vascular moves toward FDA clearance with Series B financing
Vensana Capital Closes $425 Million Fund III to Back ...